Whole-Body MRI may outshine standard scans for prostate cancer staging

NCT ID NCT03085043

Ongoing Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special whole-body MRI (diffusion-weighted imaging) can better detect prostate cancer that has spread to bones or lymph nodes compared to standard bone scans and CT scans. About 98 men with high-risk prostate cancer will undergo all three imaging methods, and researchers will compare their accuracy. The goal is to see if this MRI technique can serve as a one-stop staging tool, potentially simplifying diagnosis and improving treatment planning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Magnetic Resonance Imaging (MRI)
What this could lead to: If successful, this could make whole-body MRI a standard, more accurate way to stage high-risk prostate cancer, reducing the need for multiple scans.
What could go wrong: This is a small, early-stage study (98 participants) focused on accuracy, not treatment outcomes. The MRI method may not prove better enough to replace current scans in routine practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CARCINOMA

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.